

Weight Loss Management Prior Authorization (PA) Form

HealthKeepers, Inc. | Anthem HealthKeepers Plus Medicaid products

If the following information is not complete, correct, or legible, the PA process can be delayed. Please use one form per member.

Member Information

Last name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

First name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Medicaid ID number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Date of birth:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Weight in kilograms: _____

Prescriber information

Last name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

First name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

NPI number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Phone number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Fax number:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Drug information

****For initial requests, continue below. For renewal requests, proceed to page 4 of this form.**

All weight-loss medications will require a PA, which include, but are not limited to, the following:

Covered only for members 16 years of age or older unless otherwise specified

- | | |
|--|---|
| <input type="checkbox"/> Adipex-P®/Suprenza™ (phentermine) | <input type="checkbox"/> Alli®/Xenical® (orlistat) |
| <input type="checkbox"/> Bontril®/Bontril PDM® (phendimetrazine) | <input type="checkbox"/> Didrex®/Regimex® (benzphetamine) |
| <input type="checkbox"/> Imcivree® (setmelanotide) *ages 6 and older | <input type="checkbox"/> Ractue® (diethylpropion) |
| <input type="checkbox"/> Saxenda® (liraglutide) *ages 12 and older | <input type="checkbox"/> Wegovy® (semaglutide) *ages 12 and older |
| <input type="checkbox"/> Zepbound™ (tirzepatide) *ages 18 and older | |

(Form continued on next page.)

Member's first name:

[illegible]

Drug form:

Dosing frequency: _____

Quantity: _____

If the physician does not have the necessary information, the request will be denied and the fax form requesting additional information will be sent to the prescriber.

1. Absence of medical contraindications:

- ☐ No contraindications to use; and
- ☐ No malabsorption syndromes, cholestasis, pregnancy, and/or lactation; and
- ☐ No history of an eating disorder (for example, anorexia, bulimia)

☐ Participation in nutritional counseling; and

- ☐ Participation in physical activity program, unless medically contraindicated; and
- ☐ Commitment to continue the above weight-loss treatment plan.

☐ Prescribed by or in consultation with an endocrinologist or geneticist; and

- ☐ Member has Bardet-Biedl syndrome (BBS) or
- ☐ Member has proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency, as confirmed by a genetic test; and
- ☐ Member's genetic variants are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS)

☐ Yes ☐ No

Adipex-P®/Suprenza™, Bontril®/Bontril PDM®, Didrex®/Regimex®, Alli®/Xenical®, Radtue®:

- ☐ BMI ≥ 27 with two or more of the following risk factors: coronary heart disease, dyslipidemia, hypertension, sleep apnea, type 2 diabetes; or
- ☐ BMI ≥ 30 , if no applicable risk factors

(Form continued next page.)

Weight Loss Management Prior Authorization (PA) Form

Page 3 of 5

Member's last name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Member's first name:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Wegovy®, Saxenda®, and Zepbound™:

- ☐ BMI ≥ 27 with two or more of the following risk factors: coronary heart disease, dyslipidemia, hypertension, sleep apnea, type 2 diabetes; or
- ☐ BMI ≥ 30 and has a diagnosed disorder of the cardiovascular system (such as hypertension, dyslipidemia, prior heart attack, or stroke); OR
- ☐ BMI ≥ 30 , if no applicable risk factors; and
- ☐ Have tried and failed one of the non-GLP1 weight-loss medications 6 months prior to request
- ☐ For patients 12 to 18 years of age, a BMI that is $\geq 140\%$ of the 95th percentile by age and sex
- ☐ For patients 12 to 18 years of age, an initial BMI that is $\geq 120\%$ of the 95th percentile by age and sex with two or more of the following risk factors: coronary heart disease, dyslipidemia, hypertension, sleep apnea, type 2 diabetes.

Imcivree®:

- ☐ BMI ≥ 30 or ≥ 95 th percentile on pediatric growth chart

6. The written documentation must include the following:

- ☐ Current medical status and weight-loss plan. An individualized weight-loss program should include a specific reduced-calorie meal plan, recommended routine physical activity, and behavioral intervention, including lifestyle modification as needed to improve adherence and outcomes.
- ☐ Current accurate height and weight measurements
- ☐ No medical contraindications to use a reversible lipase inhibitor (Xenical®)
- ☐ If applicable, a 30-day trial and failure or intolerance to a non-GLP-1 weight-loss drug with a description or reason for failure or intolerance. (Saxenda®, Wegovy®, and Zepbound™)
- ☐ Member not concurrently on Victoza® or Ozempic® or other GLP-1 inhibitors (Saxenda®, Wegovy®, and Zepbound™)

(Form continued on next page.)

Page 4 of 5

Member's first name:

--	--

- Initial request: varies (drug specific)

- Benzphetamine, diethylpropion, phendimetrazine, phentermine – three months
- Wegovy®/Zepbound™ – six months
- Alli®/Xenical® – six months
- Saxenda® and Imcivree® – six months

- Phenylephrine, diethylpropion, phendimetrazine – If the member achieves at least a 10-pound (lb.) weight loss during the initial three months of therapy, an additional three-month PA may be granted. Maximum length of continuous drug therapy is six months (waiting period of 6 months before next request).
- Alli®/Xenical® – If the member achieves at least a 10-lb. weight loss, an additional 6-month PA may be granted. Maximum length of continuous drug therapy is 24 months (waiting period of 6 months before next request).
- Saxenda® – If the member achieves a weight loss of at least 4% of baseline weight, an additional six-month PA may be granted as long as weight reduction continues.
- Imcivree® – If the member has experienced $\geq 5\%$ reduction in body weight (or $\geq 5\%$ of baseline BMI in those with continued growth potential), an additional one-year PA may be granted.
- Wegovy®/Zepbound™ – If the member achieves a weight loss of at least 5% of baseline weight, an additional 6-month PA may be granted.
- Members lacking a weight-loss response may still be considered for renewal with two or more of the following weight related risk factors: coronary heart disease, dyslipidemia, hypertension, sleep apnea, type 2 diabetes.
- At this time, authorization requests over one year are subject to initial criteria, including all documentation.
- In the event of an FDA-recognized shortage, approved members will be eligible for the full allotment of approved drug once the shortage is resolved.

(Form continued on next page.)

Page 5 of 5

Member's first name:

[illegible]

Date _____

By signature, the physician confirms the above information is accurate and verifiable by member records.

Submission of documentation does **not** guarantee coverage.

The completed form may be **faxed to 844-512-7020**.